eligibility_summary
Eligible: age 1–26 (first 3: 12–26), DIPG/DMG post-radiotherapy or refractory/recurrent CNS disease without curative options, apheresis-capable, CNS reservoir catheter, life expectancy ≥8 wks, KPS/Lansky ≥60, therapy washouts met, steroids ≤2.5 mg/m2/day, adequate organs/labs, contraception. Exclude: ≥G3 cardiac, immunodeficiency, impending herniation, >G3 dysphagia (Arm A), other active cancer, severe infection, pregnant/breastfeeding, no consent, or investigator deems unsafe.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Intervention: SC-CAR4BRAIN, an autologous, lentivirally transduced, second-generation CAR T-cell therapy (CD4+ and CD8+), delivered locoregionally via intraventricular catheter. Mechanism: CAR-mediated, antigen-specific T-cell activation and cytotoxic killing of CNS tumor cells, multi-antigen design to mitigate antigen escape. CAR targets: B7-H3 (CD276, tumor-overexpressed immune checkpoint ligand), EGFR806 epitope (tumor-restricted conformational epitope on EGFR/EGFRvIII), HER2 (ERBB2), and IL13-zetakine (IL-13 mutein ligand-based CAR targeting IL13Rα2). Targeted cells/pathways: tumor cells expressing B7-H3, IL13Rα2, HER2, and aberrant EGFR, EGFR/HER2 signaling and IL13Rα2 axes in the CNS tumor microenvironment.